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Pediatric Poisoning: Overview, Treatment, and Prevention
Margaret Rowland, a fourth-year pharmacy student from Boardman, Ohio; Taylor Gauthier, a fourth-year pharmacy student from Winnebago, Ill.;
Kaitlin Sanders, a fifth-year pharmacy student from Kendallville, Ind.; Caitlin Swann, a fifth-year pharmacy student from Strongsville, Ohio;
David Bright, PharmD, assistant professor of pharmacy practice

This knowledge-based activity is targeted for all pharmacists and
is acceptable for 1.0 hour (0.1 CEU) of continuing education credit.
This course requires completion of the program evaluation and at
least a 70 percent grade on the program assessment questions.
ACPE Universal Activity Number (UAN): 0048-0000-11-025-H04-P
Objectives:
After completion of this program, the reader should be able to:
1. Describe the most common toxicity concerns in pediatric patients.
2. List the medications that pose substantial morbidity and mortality
risk in the pediatric patient with the consumption of one to two doses.
3. Name the clinical implications of common medications resulting in
poisonings.
4. Describe the role of the pharmacist in poisoning treatment recommendations and prevention.
Abstract
Pediatric poisoning remains a common and preventable occurrence in the United States. Every year, prescription and over-thecounter medications account for a significant portion of documented poison exposures. Frequent causes of overdose in children
include improper medication storage and caregiver or physician
dosing error. As easily accessible medication experts, pharmacists
have an opportunity to counsel patients in an effort to decrease
these preventable poisoning cases. Because children frequently
ingest products prescribed for adult use, pharmacists should relay
safety considerations to all patients, regardless of age. This article
provides a general review of toxicity concerns, discusses clinical
implications of common medications resulting in poisonings and
of those that are lethal in one or two doses, and describes the role
of the pharmacist in poisoning treatment recommendations and
prevention.
Background
Young children's tendency to place objects in their mouths, interest in
exploring their environment, lack of judgment, and their inability to read
make them more likely to be victims of unintentional poisoning. According to the 2009 Annual Report of the American Association of Poison
Control Center (AAPCC), approximately 52 percent of poison exposures
occurred in children five years of age and younger.1 Among the top 10
substances children were exposed to, many were common over-thecounter products such as analgesics, topical preparations, and cold
and cough preparations. An overdose of these products may occur from
repeated doses or administration errors.2 Repeated doses can occur
when more than one caregiver administers a dose of medication to a
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child or a child administers more than one dose of a medication to himself.
Administration errors are more likely to occur when dosing instructions are
misinterpreted, the weight of the child is unknown, or units on a dosing cup
or syringe are confused.
Medication errors that result in toxicity present an opportunity for pharmacist involvement to target specific products for additional patient counseling and respond to questions from concerned caregivers about potential
poisonings. Pharmacists may face questions regarding both highly toxic
medications and those that may be less toxic but more commonly result
in pediatric concern. Therefore, it is important that pharmacists be aware
and knowledgeable of both. The objective of this article is to provide a
general review of toxicity concerns, discuss clinical implications of common
medications resulting in poisonings and those that are lethal in one or
two doses, and describe the role of the pharmacist in poisoning treatment
recommendations and prevention.
Lethal in 1-2 Doses
Diphenoxylate-Atropine (Lomotil®)
The opioid antidiarrheal agent diphenoxylate-atropine is believed to cause
serious toxicity in the pediatric population through ingestion of only one or
two pills. 3 Each tablet contains a combination of 2.5 mg diphenoxylate and
0.025 mg of atropine. This product is not recommended in children under
the age of four. Children above age four have a recommended daily dose
of 0.3 to 0.4 mg/kg/24 hours in four divided doses, while the adult dose is 5
mg four times daily. All pharmacokinetic studies have been done in adults,
so there is no data available to fully understand its action in children. Serious toxicity due to ingestion of diphenoxylate-atropine is manifested as
respiratory depression, aspiration pneumonia, cerebral edema and death.
Clinical features of toxicity display both anticholinergic and opioid features
due to the combination of the two drug classes. Patients may display tachycardia, flushing, urinary retention, miosis, lethargy and even coma. Thomas, Pauze, and Love reviewed cases of reported toxicity in the pediatric
population due to exposure to diphenoxylate-atropine. 3 Children ingested
multiple tablets or were given repeat doses, which resulted in opioid side
effects such as lethargy and respiratory depression. The recommendation
is to rapidly initiate gut decontamination to avoid significant morbidity and
mortality. At this time, there is no known minimal toxic dose; the lowest reported toxic dose was ingestion of half of a tablet by a six-month-old infant.
Additionally, there is not a correlation to the quantity of drug ingested to
the severity of symptoms of toxicity. It is recommended that patients with
overdose or suspected toxicity be placed on a cardiac monitor, with frequent monitoring of vital signs and mental status changes. Since one of the
properties of the drug is to delay GI emptying, decontamination needs to be
employed either through administration of activated charcoal or via gastric
lavage. It is not advised to administer an emetic. If the patient displays
symptoms of altered mental status or respiratory depression, naloxone
should be administered. For cases of significant ingestion of diphenoxylateatropine, an observation period of 12-24 hours is recommended as well as
admittance to a pediatric intensive care unit.
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Transdermaf Patches
Use of transdermal medication administration in the pediatric population has increased in popularity and can allow for effective dosing;
however, there are also significant toxicity risks due to the thinness and
increased perfusion of their skin. 4 In order to allow the drug to reach
therapeutic levels and an adequate drug gradient, a 20-fold excess of
drug is included in transdermal drug delivery systems. Due to the high
drug content, there is a significant amount of drug remaining in patches
after their removal. The Texas Poison Central Network (TPCN) conducted a retrospective study of transdermal drug exposures from 2002
to 2006 in the pediatric population under age 12. There were 110 cases
that fell within the criteria, and the average age of children exposed
was 11.5 months. Nearly half of the exposures were via the oral route,
in which the child was found either sucking or chewing on a medicated
patch. Only 13 percent of the cases involved actual oral ingestion of
the patch. The second most common route was via dermal application
of patches. There were very few cases involving an actual therapeutic
error. Camphor or menthol patches and other over-the-counter preparations such as salicylate or nicotine patches were most often involved in
poisoning reports. Methylphenidate, often prescribed for the treatment
of ADHD in children, as well as clonidine, estrogen hormone, lidocaine,
nitroglycerin and opioid patches were also responsible for reports to the
TPCN. About 40 percent of the exposures did not result in any adverse
effects; however, one death was attributed to opioid toxicity. Six percent
of the children exposed inappropriately to transdermal patches were
hospitalized as a result of their exposure. Since 50 percent of the calls
were related to pediatric exposure to adult-based prescription medications, proper storage and disposal education is necessary for patients
who employ this dosage form.
Calcium Channel Blockers
Calcium channel blockers (CCB) are one of the most frequently prescribed classes of cardiac medications, making them highly accessible
to a curious child. 5 According to a report by the American Association
of Poison Control Centers, CCB and beta blocker ingestions are listed
in the top 10 causes of toxin-related deaths in children under the age of
six. 5 Morbidity and mortality associated with CCB toxicity are a result of
conduction delays and blocks, decreased myocardial contractility, and
loss of systemic vascular smooth muscle tone. As a result of negative
inotropic and chronotropic effects, verapamil and diltiazem overdoses
typically present with bradycardia, heart block, AV conduction disturbances and myocardial dysfunction. The most common side effect with
overdose of any CCB is hypotension. Hypoperfusion can cause a range
of effects from mild orthostasis and nausea to cerebral ischemic events
and renal failure. Despite the fact that CCBs have not been approved for
use in the pediatric population for the treatment of hypertension, several
medications, such as nifedipine and verapamil, are frequently prescribed
for hypertensive children. Ranniger and Roche conducted a retrospective review of cases involving pediatric toxicity related to CCB exposure. 5
One of the most commonly ingested CCBs was nifedipine, with 18 case
reports of toxic or fatal outcomes in toddlers. Half of the cases resulted
in death, with three of them occurring after only ingesting one or two
pills. Second was verapamil, with five of the 12 cases resulting in a fatal
outcome. Altered mental status was the most common clinical manifestation resulting from verapamil toxicity. In all of the cases reported, there
were varying doses and dosage forms (immediate vs. sustained-release)
ingested. Due to this variance, it is difficult to identify a toxic dose. Both
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extended- and sustained-release formulations can prove to be highly
toxic due to the potential of the child sucking or chewing a pill, causing an
increased dose to be released immediately. Also, the toxic dose often overlapped with nontoxic doses, further complicating toxic range identification.
Gastric lavage is not an ideal treatment as there is risk of increasing vagal
tone in cases where bradycardia or heart block are displayed. Current recommendations suggest that activated charcoal be administered within two
hours of CCB ingestion, with monitoring for six hours for regular-release
products and up to 24 hours for sustained-release medications.
Camphor
Camphor is an aromatic terpene ketone used topically as an analgesic, antipruritic and antitussive agent. Camphor is present in topical preparations
like Vicks VapoRub® and BenGay®. At doses as little as 500 mg, camphor
has been shown to cause death; just 4 teaspoons of Vicks VapoRub could
be fatal. Early clinical manifestations of toxic exposure are gastrointestinal
upset and a general sensation of warmth. Symptoms can progress rapidly
from a phase of CNS hyperactivity, including excitement, restlessness,
delirium and seizures, to a phase of CNS depression with coma and respiratory depression. There is no specific antidote for camphor poisoning;
however, supportive treatment involving seizure control and airway management is employed. Referral to the emergency room is recommended for
patients ingesting 500 mg or more of camphor. 6•7
Saficylate
Salicylate can be found in aspirin, Pepto-Bismol® and oil of wintergreen
and is thought to be toxic at levels of 150 mg/kg. Oil of wintergreen, a
common food flavoring, has the highest salicylate content. One teaspoonful contains four times the dose of salicylate thought to be toxic in a 1Okg
child. Almost 90 baby aspirin would be needed to reach the same toxic
level. Additionally, the half-life of salicylate in children increases from two
to four hours at therapeutic levels to 15-29 hours at toxic levels. Signs
of toxicity are nausea, vomiting, diaphoresis, tinnitus, agitation, delirium,
hallucinations and lethargy. Salicylate ingestion stimulates the respiratory
center in the brainstem, causing hyperventilation and hyperpnea. High levels of ingested salicylates may cause pulmonary edema, cerebral edema,
coma and death. Classic laboratory findings for salicylate toxicity include
an acid-base disturbance present as an anion gap metabolic acidosis with
respiratory alkalosis. Management of salicylate poisoning should begin
with determination of serum salicylate concentrations. Treatment options
consist of supportive care, gastric decontamination, urine alkalinization to
enhance salicylate elimination, and hemodialysis. 6•7
Suffonyfureas
Sulfonylureas such as glyburide and glipizide are oral hypoglycemic
agents commonly used in the management of type 2 diabetes. In 2009, the
AAPCC documented 922 exposures to sulfonylureas in children less than
five. 1 Literature suggests ingestion of only one or two tablets in a toddler
has the potential to cause hypoglycemia, neurologic sequelae and, potentially, death. 8 Signs of hypoglycemia in young children include weakness,
fussiness, dizziness, change in behavior, seizure, decreased appetite and
focal neurologic deficit. Little and Boniface reviewed available literature
on pediatric sulfonylurea exposures and formulated recommendation
guidelines. 8 Because children younger than six have small glycogen stores,
recommendations for suspected sulfonylurea ingestions currently favor
hospitalization and eight hours of observation with hourly serum glucose
monitoring, even when asymptomatic. The observation period should be
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extended if glipizide XL consumption is suspected due to its delayed
peak time. If hypoglycemia is detected, blood glucose level determination and stabilization is imperative. Appropriate treatment in symptomatic
patients includes IV administration of a dextrose bolus and continuation
of monitoring for several hours after the infusion. A continuous infusion
of glucose may be required and should be considered on a case-to-case
basis. In patients who are refractory to IV glucose administration, treatment with octreotide and diazoxide may be considered. Although controversial, activated charcoal may be given within one hour of ingestion.8
Common Prescription Medications of Concern
Montelukast
Montelukast has been approved for use in the pediatric population for
chronic treatment of asthma and allergic rhinitis. 9 For patients six to
14 years old, the daily dose is 5 mg, and for children under six years
old, it is 4 mg. There have been few adverse effects with ingestion of
montelukast, typically headache, influenza, abdominal pain, cough and
dizziness. A review of reports from the AAPCC did not cite any deaths
associated with ingestion of montelukast. A TPCN retrospective study
identified pediatric montelukast ingestion in patients ranging from age
zero to five years old that were reported to their center between 2000
and 2005. During the study time period, there were a total of 3,698
reports. The number of tablets ingested ranged from <1to134. Almost
all of the cases reported had an outcome that could be classified as no
effect, and there were no major adverse events or deaths. Most cases
could be treated at home, with only a small number of patients needing
to seek medical attention. The suggested home treatment is decontamination, which can be accomplished by dilution and food. In the medical setting, activated charcoal followed by a cathartic was employed.
Observations made from this study indicate that pediatric ingestions of
montelukast up to 536 mg or 33.71 mg/kg are not likely to result in any
major adverse clinical events.
Atomoxetine
Atomoxetine hydrochloride is indicated for use in pediatric patients
with attention-deficit/hyperactivity disorder (ADHD). 10 Dosing initiates at 0.5 mg/kg with titration up to the target dose of 1.2-1.4 mg/kg/
day. The recommended daily dose has relatively low adverse effects,
including dyspepsia, nausea, vomiting, rash, decreased appetite and
weight loss. Stojanovski et al. conducted a retrospective study of calls
received in 2004 at a regional poison control center in Ohio, with the
goal of establishing adverse drug reactions and toxicities in the pediatric
population. The mean dose reported was 85 ± 59.6 mg, and only 33
percent of the cases reported adverse drug reactions: agitation, headache, erythema, rash, elevated blood pressure and heart rate, emesis
and nausea, and lethargy. Over half of these cases could be observed
at home. Those requiring medical treatment received either activated
charcoal or activated charcoal and a cathartic. All of the cases identified
had resolution of adverse effects within 24 hours. The most severe case
identified a 15-year-old boy who had ingested 1,200 mg (22 mg/kg) and
experienced both seizures and cardiac conduction delays. His treatment
was aggressive and included activated charcoal, intravenous fluids,
diazepam, and phenytoin. Because it is difficult to identify children at low
risk of developing adverse reactions, it is recommended all atomoxetine
exposures be referred to the emergency department for observation,
monitoring of vital signs, and possibly gastric decontamination.
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Angiotensin Converting Enzyme (ACE) Inhibitors
The angiotensin converting enzyme (ACE) inhibitor lisinopril has been found
to be both safe and effective as a treatment for hypertension in children age
six to 16; however, safety in younger populations has not been adequately
evaluated. 11 Previous study findings have indicated that ingestion of <1 mg/
kg is able to be managed at home. The TPCN conducted a retrospective
study using data collected on lisinopril ingestions from 1998-2005 in patients
under age six in order to propose triage guidelines for pediatric ingestion
of lisinopril. The maximum dose was 32.8 mg or 2.6 mg/kg, but typically
the child had ingested only one tablet. Ingestion was usually a result of
the child accessing someone else's medication, a parent giving the child
the wrong medication, or a pharmacy filling error. In 95.7 percent of the
cases reviewed, there were no serious outcomes. Adverse clinical effects
observed included hypotension, vomiting and drowsiness. Decontamination
with food and dilution was most often used, and activated charcoal was
employed when serious outcomes were found. More severe cases required
the administration of IV fluids and vasopressors when managing hypotension. The triage guidelines indicate that for doses s 4 mg/kg, s 80 mg, or s 5
tablets, home management is adequate.11
Analgesics
The most frequently reported drug exposures reported to poison control
centers (PCC) are analgesics. 12 Since acetaminophen is the antipyreticanalgesic most commonly used in children, it is one of the most commonly
ingested. Poison control centers received a quarter of a million calls from
2000 to 2003 regarding acetaminophen poisoning. Angalakuditi, Coley, and
Krenzelok conducted a retrospective review of acetaminophen exposures
in children less than 18 years of age, occurring between Oct. 31, 2000, and
Oct. 31, 2003, that were managed by an MPCC-certified regional poison
control center (RPCC). There were 473 pediatric exposures identified, 75.9
percent of which occurred in children younger than six years of age. The
mean dose of acetaminophen reported was 3,685 ± 6,985 mg. Hepatotoxicity risk is associated with acute acetaminophen ingestions of 150-200 mg/
kg; mortality is rare. Since acetaminophen poisoning is a preventable injury,
health care professionals have a critical role in patient education. Parents
should be educated on medications they are giving their children, specifically nonprescription drugs, since they are more likely to rely on caregiver
interpretation of directions and be administered to young children. Astudy
by Snyder reported that 88 percent of parents who were administering
nonprescription medications to their children were not adequately educated
on the medication itself. In a mock exercise, only 40 percent of caregivers
could correctly state the dosage of acetaminophen for their child, and only
43 percent could measure the correct dose.
Dosing Errors
Research suggests that dosing errors are the most frequent type of therapeutic error in the pediatric population, largely due to the increased calculations involved when prescribing, dosing and administering medications
to children. 13- 15 Pediatric patients may have rapidly changing body weights
and changing pharmacokinetic parameters that require dose recalculation.
Other sources of error are off-label use of medications and the inability
of young children to communicate with their provider. Most institutional
dosing errors are commonly related to antibiotic dosing. 13•16·17 Error in antibiotic dosing has been shown to occur in neonates less than seven days
old when doses are not modified with their maturation and changing body
weight. Errors also have been associated with the administration of fluids
and electrolytes as well as dilution of intravenous medications. 16
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The most common type of dosing error is the tenfold dosing error.
The 2009 Annual AAPCC Report stated that more than 50 percent of
all tenfold dosing errors occurred in children under age six. 1 A tenfold
dosing error results in the administration of a dose 10 times higher or
lower than the intended dose. Errors may be caused by miscalculations,
transcription errors, the use of incorrect units, placing a terminal zero to
the right of a decimal point (12.0 rather than 12), or not placing a zero to
the left of a decimal point (.8 instead of 0.8). Tenfold dosing errors have
higher incidence of fatal outcomes because they tend to be associated
with a higher chance of toxicity or lack of efficacy than other types of
errors. 14

How Pharmacists Can Help
As a pharmacist, performing medication therapy intervention (MTI) can
help identify prescribing errors. A two-week study was conducted in the
community pharmacy setting in which pharmacists in five states submitted
an MTI form to document pharmacist actions taken to resolve electronic
prescribing problems. 18 The overall intervention rate was found to be 3.8
percent, with most interventions being to supplement missing information
and correct inappropriate dosing. Most pharmacists resolved the problem
by contacting the prescriber, and over half of all interventions ended in a
change to the prescription betore dispensing to the patient.
Pharmacists can help prevent accidental poisoning of children by educating parents and caregivers about ways to reduce therapeutic errors (Table
1), proper medication storage out of the reach of children, and the difference between child-resistant and child-proof containers. Child-resistant
does not mean child-proof. 19 Child-resistant packaging is designed to be
easy for adults to open, but significan~y difficult for children under five
years of age to open within a reasonable period of time. Eighty-five percent
of children under the age of five should not be able to open the package
in a five-minute time period. Pharmacists should promote the use of childresistant caps to patients that have children or have children visit them. For
patients that find the caps difficult to open, the pharmacist can demonstrate
their use. In states that allow a blanket request for non-child-resistant caps,
a pharmacist may want to periodically ensure that patients who opt out of
this safety measure understand the increased risk of child poisoning that
may occur.

Table 1: Caregiver strategies for reducing therapeutic errors2
·Avoid distractions when administering medications
• Double-check all medications and doses prior fo administration
with another person if possible
• Communicate with other medication administrators
• Record when a dose is given
• Advise other caregiver that dose was given
• Have only one caregiver administer all doses
• Have specific storage for
• Each person's medication
• Internal and non-internal medications
• Medications taken at different times of day
• Make sure measuring devices are familiar and have clear markings
• Only keep one strength of a medication if possible
• Clearly label the dosage instructions and routes of administration
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Conclusion
In general, pediatric poisoning is a common and preventable occurrence.
Counseling often only occurs on pediatric medications, but common and
often more serious ingestions also involve products rarely used in or contraindicated in children; therefore, pharmacists should relay safety considerations to all patients, regardless of age. As easily accessible medication
experts, pharmacists should intervene in an effort to decrease preventable
poisoning cases in children.
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Assessment Questions
1. All of the following statements regarding salicylate toxicity are true
except:
a. In children, the half-life of salicylate is independent of the
amount of salicylate ingested.
b. Salicylate toxicity presents as an anion gap metabolic acidosis
with respiratory alkalosis.
c. Salicylate stimulates the respiratory center in the brainstem and
can cause hyperventilation.
d. Pepto-Bismol, aspirin, and oil of wintergreen all contain salicylate.
2. Dosing errors in the pediatric population occur when:
a. There is failure to recalculate doses for maturing patients with
changing body weights
b. A tenfold dosing error is made
c. Intravenous medications are not properly dilute
d. All of the above
3. What is the suggested treatment for a child who has ingested montelukast and is being observed at home?
a. Nothing
b. Decontamination with food and fluids
c. Administration of a cathartic
d. None of the above

8. The smallest reported toxic dose of diphenoxylate-atropine is:
a.% tablet
b. 1 tablet
c. 2 tablets
d. 4 tablets
9. Which Calcium Channel Blockers (CCBs) are the most likely to be
involved in severe toxicity that result in death?
a. Amlodipine
b. Nifedipine
c. Verapamil
d. A and C
e. Band C
10. Appropriate management strategies for suspected sulfonylurea
exposures in children less than 6 include:
a. Home observation for asymptomatic patients
b. Glucose bolus administration in symptomatic patients
c. Octreotide use in glucose resistant patients
d. Band C
Ohio Northern University is accredited by the Accreditation
Council for Pharmacy Education as a provider of continuing
pharmacy education. This program is eligible for credit until
, April 5, 2014.

4. What is (are) the recommendation(s) for atomoxetine exposure?
a. Emergency department observation
b. Vital sign monitoring
c. Gastric decontamination
d. All of the above
5. Which Angiotensin Converting Enzyme (ACE) Inhibitor has been approved for treatment of hypertension in children age 6 to 16 years?
a. Captopril
b. Fosinopril
c. Lisinopril
d. Ramipril
6. What is the most common route of unintended exposure of transdermal patches in the pediatric population?
a. Dermal
b. Oral
c. Rectal
d. Intravenous
7. Drug exposures of which class are most commonly reported to poison
control centers?
a. Analgesics
b. ACE Inhibitors
c. Beta-Blockers
d. HMG-CoA Ruductase Inhibitors

27

The Pharmacy and Wellness Review

Volume two, Issue two

May 2011

To receive continuing education credit for this program, visit www.onu.edu/pharmacy/CE OR fill out the form below
including your indicated answers to the assessment questions and return to:
Office of Continuing Education at tbe Raabe College of Pharmacy
Ohio Northern University
525 South Main Street
Ada, Ohio 45810

Program Title:

Pediatric Poisoning: Overview, Treatment and Prevention
UAN: 0048-0000-ll-025-H04-P
CEU's: 0.1
All information must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of
continuing education credit. Certificates will be distributed as a PDF document to a valid Email address.

Name:
Address:
City:

State:

Phone:

E-mail

Pharmacy License #:

State:

Zip:

ONU Alumni?

Y

2

3

4

5

Describe the most common toxicity concerns in pediatric patients.

2

3

4

5

List the medications that pose substantial morbidity and mortality risk in the
pediatric patient with the consumption of one to two doses.

2

3

4

5

Name the clinical implications of common medications resulting in poisonings.

2

3

4

5

Describe the role of the pharmacist in poisoning treatment recommendations
and prevention.

2

3

4

5

The program met your educational needs.

2

3

4

5

Content of the program was interesting.

2

3

4

5

Material presented was relevant to my practice.

2

3

4

5

The program objectives were clear.

N

The program met the stated goals & objectives;

Comments/Suggestions for future programs:

Thank You!
Answers to Assessment Questions - Please Circle Your Answer
1.A BCD

4.A BCD

7.A BCD

2.A BCD

5.A BCD

8.A BCD

3.A BCD

6.A BCD

9.A BCD

~.

10.A BCD

Ohio Northern University is accredited by the Accreditation Council for Pharmacy Education as a provider of
continuing pharmacy. This program is eligible for credit until April 5, 2014

Any questions/comments regarding this continuing education program can be directed to Lynn Bedford, advanced administration assistant
for the Office of Continuing Education, at l-bedford@onu.edu or 419-772-1871.

